Peter Juni
Latest contributions
Innovative strategies for coronary interventions
22 May 2025 – From EuroPCR 2025
Explore innovative strategies in coronary interventions, including the EPIC26 sirolimus-eluting stent study, use of percutaneous ventricular assist devices in high-risk patients, the SCORE multicenter study on SeQuent SCB, DCB versus DES for ostial left circumflex lesions, and site-specific antithrombotic therapy outcomes from the DESyne BDS Plus...
Hotline TAVI 3: Challenging anatomical and clinical scenarios
22 May 2025 – From EuroPCR 2025
This hotline session presents challenging anatomical and clinical scenarios in TAVI, including outcomes in bicuspid aortic valve patients, chronic aortic regurgigation, comparisons of surgical versus percutaneous approaches, and real-world data on valve performance and resource utilization.
Inludes:
- Five-year outcomes from the Evolut low risk TAVR bicuspid study
- Surgical versus...
Multi-modality assessment of coronary disease
21 May 2025 – From EuroPCR 2025
This session offers comprehensive multi-modality assessment of coronary disease, integrating advanced imaging and functional testing. Topics include diagnostic yield of OCT and cardiac MRI for MINOCA, transitioning coronary plaque vulnerability assessment from invasive to non-invasive methods, relationships between QFR and IVUS post-PCI in complex lesions, combined...
DES and bioadaptator technologies in contemporary practice
21 May 2025 – From EuroPCR 2025
Delve into contemporary practice with this session on drug-eluting stents (DES) and bioadaptator technologies. Gain insights from international studies on complex PCI outcomes, comparative data from randomized trials, and real-world experiences focusing on high bleeding risk patients and elderly cohorts treated with ultrathin strut and new-generation...
Has the 2023 ESC-EACTS guideline review on left main changed my practice?
15 May 2024 – From EuroPCR 2024
Watch this session if you wish to learn why the 2019 guidelines were revised, how to apply the updated recommendations in clinical settings through case examples, and the criteria for selecting patients with left main stenosis for PCI versus CABG.
The session includes detailed presentations on...
TAVI 1: durability, mismatch and challenging anatomy
18 May 2023 – From EuroPCR 2023
Explore TAVI longevity: Five-year Portico valve outcomes, bioprosthetic dysfunction post-surgery or self-expanding TAVI, prosthesis-patient mismatch impact, and innovative valve-in-valve TAVI insights, and more.
How to understand the ISCHEMIA trial?
27 Jun 2020 – From PCR e-Course 2020
Watch this session if you want to get a better understanding of what the ISCHEMIA trial is about and what it is not about, and to make up your own opimind on the strength of the ISCHEMIA conclusions based on its methodology and results.
This session was...
Trials and registries - Managing bleeding risk in search of optimal drug-device synergy
23 May 2019 – From EuroPCR 2019
Consult this session to discover the results of the latest trials and registries for the management of bleeding risk in search of optimal drug-device synergy: ROBOT-ACS, GLOBAL LEADERS, SAFE-A, and more!
Will the Evolut Low Risk trial change my practice?
22 May 2019 – From EuroPCR 2019
Consult this session to learn all about the Evolut Low Risk TAVI trial, whose goal was to assess the safety and efficacy of transcatheter aortic valve replacement with the self-expanding CoreValve, compared with surgical aortic valve replacement in low-risk patients. Discover how its results apply to your practice!
EuroPCR 2019 Hot Line and Trial Update
21 May 2019 – From EuroPCR 2019
Consult this session to learn all about the results of the latest trials : discover more about the COAPT trial, examining the relationship between residual mitral regurgitation and clinical outcomes, the GLOBAL Leaders substudy, examining ticagrelor monotherapy in complex PCI, and the BIO-RESORT, determining the clinical outcomes following treatment...
Will the PARTNER 3 Low Risk trial change my practice?
21 May 2019 – From EuroPCR 2019
Consult this session to learn more about the relevance of the PARTNER 3 Low Risk TAVI trial, how the results apply to specific patients and how they may impact your clinical practice.
